Loading...
 
Toggle Health Problems and D

Ovarian Cancer re-occurrence 50 percent more likely if still low vitamin D – Sept 2015

Low 25-OH vitamin D levels at time of diagnosis and recurrence of ovarian cancer

Tumor Biology DOI: 10.1007/s13277-015-4055-1
Teresa Granato, Lucia Manganaro, Luca Petri, Maria Grazia Porpora, Valentina Viggiani, Antonio Angeloni, Emanuela Anastasi emanuela.anastasi at uniroma1.it

VitaminDWiki


The objective of this study was to evaluate the correlation between 25-OH vitamin D and ovarian cancer as a diagnostic marker or recurrence disease marker. We studied the following: (1) 61 women without gynecologic diseases, (2) 45 women affected by benign ovarian disease, (3) 46 women with recent diagnosis of ovarian cancer, (4) 26 follow-up women with recurrent ovarian cancer, and (5) 32 follow-up women with stable ovarian cancer. The 25-OH vitamin D was quantified with LUMIPULSE® G 25-OH vitamin D on LUMIPULSE® G 1200 (Fujirebio, Japan). As a threshold value, identified by ROC curve analysis, 20.2 ng/mL (sensitivity 73.3 %, specificity 84 %) was chosen corresponding to the limit between sufficient and insufficient 25-OH vitamin D according to the WHO. Low 25-OH vitamin D levels were observed in 26 % of women without gynecologic diseases, in 80 % of women with recent diagnosis of ovarian cancer and in 24 % women affected by benign ovarian diseases (p < 0.001).
The follow-up study showed an insufficient level of 25-OH vitamin D in

  • 73 % women with recurrent ovarian cancer and in
  • 47 % women with stable ovarian cancer (p < 0.0003).

This study showed that patients with ovarian cancer are often insufficient in 25-OH vitamin D compared to women with benign ovarian diseases. The women with recurrent ovarian cancer presented more often low levels compared to women with stable ovarian cancer. This study suggests that 25-OH vitamin D, due to its antiproliferative properties, can be a good marker for ovarian cancer also.

Publisher wants $40 for PDF

References

  • 1.Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, ESMO Guidelines Working Group, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:24–32.CrossRef
  • 2.Li K, Hüsing A, Fortner RT, Tjønneland A, Hansen L, Dossus L, et al. An epidemiologic risk prediction model for ovarian cancer in Europe: the EPIC study. Br J Cancer. 2015;5. doi:10.​1038/​bjc.​2015.​22.
  • 3.di Masi A, Leboffe L, De Marinis E, Pagano F, Cicconi L, Rochette-Egly C, et al. Retinoic acid receptors: from molecular mechanisms to cancer therapy. Mol Aspects Med. 2015;41C:1–115.CrossRef
  • 4.Xie J, Poole EM, Terry KL, Fung TT, Rosner BA, Willett WC, et al. A prospective cohort study of dietary indices and incidence of epithelial ovarian cancer. J Ovarian Res. 2014;7(1):112–4.PubMed CentralCrossRefPubMed
  • 5.Wang G, Zhang Q, Xu N, Xu K, Wang J, He W, et al. Associations between two polymorphisms (FokI and BsmI) of vitamin D receptor gene and type 1 diabetes mellitus in Asian population: a meta analysis. PLoS One. 2014;9(3):e89325.PubMed CentralCrossRefPubMed
  • 6.Attar R, Gasparri ML, Donato VD, Yaylim I, Halim TA, Zaman F, et al. Ovarian cancer: interplay of vitamin D signaling and miRNA action. Asian Pac J Cancer Prev. 2014;15(8):3359–62.CrossRefPubMed
  • 7.Watanabe R, Inoue D. Current topics on vitamin D. Anti-cancer effects of vitamin D. Clin Calcium. 2015;25(3):373–80.PubMed
  • 8.Wranicz J, Szostak-Węgierek D. Health outcomes of vitamin D. Part II. Role in prevention of diseases. Rocz Panstw Zakl Hig. 2014;65(4):273–9.PubMed
  • 9.Gandini S, Gnagnarella P, Serrano D, Pasquali E, Raimondi S. Vitamin D receptor polymorphisms and cancer. Adv Exp Med Biol. 2014;810:69–105.PubMed
  • 10.Shui IM, Mondul AM, Lindström S, Tsilidis KK, Travis RC, Gerke T,et al. Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer. 2015;2. doi:10.​1002/​cncr.​29320.
  • 11.Nemazannikova N, Antonas K, Dass CR. Vitamin D: metabolism, molecular mechanisms, and mutations to malignancies. Mol Carcinog. 2014;53(6):421–31.CrossRefPubMed
  • 12.Li S, Xu H, Li SC, Qi XQ, Sun WJ. Vitamin D receptor rs2228570 polymorphism and susceptibly to ovarian cancer: a meta-analysis. Tumour Biol. 2014;35(2):1319–22.CrossRefPubMed
  • 13.Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014;133(3):401–4. doi:10.​1016/​j.CrossRefPubMed
  • 14.Bonfrer JM, Duffy MJ, Kulpa J, Rustin GJ, Soletormos G, Torre GC, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005;15:679–91.CrossRefPubMed
  • 15.Aebi S, Castiglione M. Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis; treatment and follow-up. Ann Oncol. 2009;20(Supp4):iv21–3.
  • 16.Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ. Staging of advanced ovarian cancer: comparison of imaging modalities—report from the Radiological Diagnostic Oncology Group. Radiology. 2000;215:761–7.CrossRefPubMed
  • 17.Manganaro L, Michienzi S, Vinci V, Falzarano R, Saldari M, Granato T, et al. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer. Oncol Rep. 2013;30:2481–7.PubMed
  • 18.Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2009;71:164–74.CrossRefPubMed
  • 19.Midulla C, Manganaro L, Longo F, Viggiani V, Frati L, Granato T, et al. HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma. Tumour Biol. 2012;33:1291–8.CrossRefPubMed
  • 20.Falzarano R, Viggiani V, Michienzi S, Longo F, Tudini S, Frati L, et al. Evaluation of a CLEIA automated assay system for the detection of a panel of tumor markers. Tumour Biol. 2013;34(5):3093–100.CrossRefPubMed
  • 21.Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol. 2002;20:1161–3.PubMed
  • 22.Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:23–30.CrossRef
  • 23.Bast Jr RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415–28.PubMed CentralCrossRefPubMed
  • 24.Lynch HT, Drescher K, Knezetic J, Lanspa S. Genetics biomarkers, hereditary cancer syndrome diagnosis, heterogeneity and treatment: a review. Curr Treat Options Oncol. 2001;15:429–42.CrossRef
  • 25.Guideline No. 62RCOG/BSGE Joint Guideline Royal College guidelines 2011. Management of suspected ovarian masses in premenopausal women. Green-top.
  • 26.Mutch D, Denny L, Quinn M. FIGO Committee on Gynecologic Oncology. Hereditary gynecologic cancers. Int J Gynaecol Obstet. 2014;124:189–92.CrossRefPubMed
  • 27.Granato T, Porpora MG, Longo F, Angeloni A, Lucia Manganaro L, Anastasi E. He4 in the differential diagnosis of ovarian masses. Clin Chim Acta. 2015;446:147–55.CrossRefPubMed
  • 28.Walentowicz-Sadłecka M, Sadłecki P, Walentowicz P, Grabiec M. The role of vitamin D in the carcinogenesis of breast and ovarian cancer. Ginekol Pol. 2013;84(4):305–8.PubMed
  • 29.Irazoqui AP, Boland RL, Buitrago CG. Actions of 1,25(OH)2-vitamin D3 on the cellular cycle depend on VDR and p38 MAPK in skeletal muscle cells. J Mol Endocrinol. 2014;53(3):331–43.CrossRefPubMed
  • 30.Low RN, Sebrechts CP, Barone RM, Muller W. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings--a feasibility study. AJR Am J Roentgenol. 2009;193:461–70.CrossRefPubMed
  • 31.Irving AA, Plum LA, Blaser WJ, Ford MR, Weng C, Clipson L, et al. Cholecalciferol or 25-hydroxycholecalciferol neither prevents nor treats adenomas in a rat model of familial colon cancer. J Nutr. 2015;145(2):291–8.CrossRefPubMed

See any problem with this page? Report it (FINALLY WORKS)